Test 4
Hyperhomocysteinemia
Center for Health Sciences, SerbiaUNKNOWNPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Hyperhomocysteinemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Folic Acid Shenzhen Ausa Pharmed Co.,Ltd | Phase 4 | BBB |
Enalapril Maleate Fuling Central Hospital of Chongqing City | Phase 4 | BB |
Folate Universidade Estadual de Londrina | Phase 4 | BB |
AMLODIPINE Shenzhen Ausa Pharmed Co.,Ltd | Phase 4 | BB |
PYRIDOXOL Center for Health Sciences, Serbia | Phase 3 | BB |
Vibisone Georgetown University | N/A | D |
L-5-MTHF IRCCS Azienda Ospedaliero-Universitaria di Bologna | N/A | D |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →